The Safety and Efficacy of Targeted Alpha Therapy, Ac‐225 Prostate‐Specific Membrane Antigen, in Patients With Metastatic Castration‐Resistant Prostate Cancer: A Systematic Review and Meta‐Analysis
The Prostate · 2025
DOI: 10.1002/pros.24857 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Prostate, 2025. Verfasst von Huseyin Besiroglu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Istanbul, Turkey. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Actinium, Alpha Particles, Glutamate Carboxypeptidase II. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Background
Metastatic castration resistance prostate cancer (mCRPC) is a challenging disease with a significant burden of mortality and morbidity. Most of the patients attain resistance to the available treatments, necessitating further novel therapies in this clinical setting. Actinium 225 ( 225 Ac) prostate‐specific membrane antigen (PSMA) radioligand therapy has emerged as a promising option and has been utilized for the last decade. Although a few meta‐analyses were performed on the efficacy and safety of 225 Ac‐PSMA RLT in mCRPC patients, several current studies have been added to the literature since the latest meta‐analysis. We aimed to gather all individual studies to perform up‐to‐date meta‐analyses.
Methods
We searched the literature using Pubmed‐Medline, Web of Science, Elsevier‐Sceince Direct, and Cochrane‐Central databases. The data for any PSA decline, over 50% PSA decline, overall survival (OS), progression‐free survival (PFS), and toxicity profile were captured from the studies eligible for meta‐analysis. We utilized the random effect model to generate pooled estimates.
Results
The sixteen eligible studies contained 1102 patients. Sixty‐three percent of patients achieved more than 50% PSA decline, while 82% had any PSA decline after the completion of therapy. The pooled mean OS and PFS were 12.72 months (9.52–15.91) and 11.02 months (6.88–15.15), respectively. The most common adverse event was xerostomia, with a pooled proportion of 84%. Grade ≥ 3 anemia, thrombocytopenia, leucopenia, and nephrotoxicity were encountered in 9%, 5%, 4%, and 4% of the patients.
Conclusions
225 Ac‐PSMA RLT is an efficacious and safe treatment for mCRPC. Future well‐designed randomized controlled studies comparing 225 Ac‐PSMA RLT with other approved therapeutic options would better comprehend the exact role of this therapy in the treatment sequence of mCRPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Istanbul, Turkey.
ORCID-Profile: Huseyin Besiroglu
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Besiroglu, H., & Kadihasanoglu, M. (2025). The Safety and Efficacy of Targeted Alpha Therapy, Ac‐225 Prostate‐Specific Membrane Antigen, in Patients With Metastatic Castration‐Resistant Prostate Cancer: A Systematic Review and Meta‐Analysis. The Prostate. https://doi.org/10.1002/pros.24857
Vancouver
Besiroglu H, Kadihasanoglu M. The Safety and Efficacy of Targeted Alpha Therapy, Ac‐225 Prostate‐Specific Membrane Antigen, in Patients With Metastatic Castration‐Resistant Prostate Cancer: A Systematic Review and Meta‐Analysis. The Prostate. 2025. doi:10.1002/pros.24857
BibTeX
@article{Besiroglu2025,
author = {Besiroglu, Huseyin and Kadihasanoglu, Mustafa},
title = {The Safety and Efficacy of Targeted Alpha Therapy, Ac‐225 Prostate‐Specific Membrane Antigen, in Patients With Metastatic Castration‐Resistant Prostate Cancer: A Systematic Review and Meta‐Analysis},
journal = {The Prostate},
year = {2025},
doi = {10.1002/pros.24857}
}
EUVIMED